Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19018658.
- Also identified by DOI 10.1371/journal.pmed.0050227 and PMC identifier 2586344.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.
Medical subject headings
- Antimalarials
- Clinical Trials, Phase III as Topic
- Malaria, Falciparum